• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Keros Therapeutics, Inc. - common stock (NQ:KROS)

14.32 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 261,048
Open 14.31
Bid (Size) 13.10 (2)
Ask (Size) 15.45 (4)
Prev. Close 14.32
Today's Range 14.25 - 14.50
52wk Range 9.120 - 72.37
Shares Outstanding 23,337,862
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
June 10, 2025
BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns. 
Via Benzinga
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
May 29, 2025
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review. 
Via Benzinga

Performance

YTD
-10.1%
-10.1%
1 Month
+7.3%
+7.3%
3 Month
-1.7%
-1.7%
6 Month
+22.3%
+22.3%
1 Year
-71.5%
-71.5%

More News

Read More
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price
April 11, 2025
Via Benzinga
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan
April 10, 2025
Via Benzinga
Analyst Expectations For Keros Therapeutics's Future
February 27, 2025
Via Benzinga
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)
January 17, 2025
Via Benzinga
Where Keros Therapeutics Stands With Analysts
December 16, 2024
Via Benzinga
These stocks are gapping in today's session
April 10, 2025
Via Chartmill
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed
April 10, 2025
Via Stocktwits
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump
April 10, 2025
Via Benzinga
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
April 10, 2025
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 10, 2025
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Keros Therapeutics
April 01, 2025
Via Benzinga
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm
January 24, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)
January 22, 2025
From Kirby McInerney LLP
Via Business Wire
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views
January 15, 2025
Via Benzinga
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results
January 15, 2025
Via Benzinga
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes
January 15, 2025
Via Stocktwits
Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS
December 17, 2024
Via ACCESSWIRE
Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS
December 16, 2024
Via ACCESSWIRE
Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud
December 16, 2024
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 12, 2024
Via Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
December 12, 2024
Via Benzinga
Topics Stocks
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
December 12, 2024
Via Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
December 12, 2024
Via Benzinga

Frequently Asked Questions

Is Keros Therapeutics, Inc. - common stock publicly traded?
Yes, Keros Therapeutics, Inc. - common stock is publicly traded.
What exchange does Keros Therapeutics, Inc. - common stock trade on?
Keros Therapeutics, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Keros Therapeutics, Inc. - common stock?
The ticker symbol for Keros Therapeutics, Inc. - common stock is KROS on the Nasdaq Stock Market
What is the current price of Keros Therapeutics, Inc. - common stock?
The current price of Keros Therapeutics, Inc. - common stock is 14.32
When was Keros Therapeutics, Inc. - common stock last traded?
The last trade of Keros Therapeutics, Inc. - common stock was at 08/01/25 04:00 PM ET
What is the market capitalization of Keros Therapeutics, Inc. - common stock?
The market capitalization of Keros Therapeutics, Inc. - common stock is 334.20M
How many shares of Keros Therapeutics, Inc. - common stock are outstanding?
Keros Therapeutics, Inc. - common stock has 334M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap